التفاصيل البيبلوغرافية
| العنوان: |
In Silico Computational Studies of Bioactive Secondary Metabolites from Wedelia trilobata against Anti-Apoptotic B-Cell Lymphoma-2 (Bcl-2) Protein Associated with Cancer Cell Survival and Resistance. |
| المؤلفون: |
Gowtham, Hittanahallikoppal Gajendramurthy, Ahmed, Faiyaz, Anandan, Satish, Shivakumara, C. S., Bilagi, Ashween, Pradeep, Sushma, Shivamallu, Chandan, Shati, Ali A., Alfaifi, Mohammad Y., Elbehairi, Serag Eldin I., Achar, Raghu Ram, Silina, Ekaterina, Stupin, Victor, Murali, Mahadevamurthy, Kollur, Shiva Prasad |
| المصدر: |
Molecules; Feb2023, Vol. 28 Issue 4, p1588, 16p |
| مصطلحات موضوعية: |
METABOLITES, B cells, MOLECULAR dynamics, BCL-2 proteins, CELL survival, CANCER cells, B cell receptors |
| مصطلحات جغرافية: |
AMES (Iowa) |
| مستخلص: |
In the present study, the binding affinity of 52 bioactive secondary metabolites from Wedelia trilobata towards the anti-apoptotic B-cell lymphoma-2 (Bcl-2) protein (PDB: 2W3L) structure was identified by using in silico molecular docking and molecular dynamics simulation. The molecular docking results demonstrated that the binding energies of docked compounds with Bcl-2 protein ranged from −5.3 kcal/mol to −10.1 kcal/mol. However, the lowest binding energy (−10.1 kcal/mol) was offered by Friedelin against Bcl-2 protein when compared to other metabolites and the standard drug Obatoclax (−8.4 kcal/mol). The molecular dynamics simulations revealed that the Friedelin-Bcl-2 protein complex was found to be stable throughout the simulation period of 100 ns. Overall, the predicted Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) properties of Friedelin are relatively better than Obatoclax, with the most noticeable differences in many parameters where Friedelin has no AMES toxicity, hepatotoxicity, and skin sensitization. The ADMET profiling of selected compounds supported their in silico drug-likeness properties. Based on the computational analyses, the present study concluded that Friedelin of W. trilobata was found to be the potential inhibitor of the Bcl-2 protein, which merits attention for further in vitro and in vivo studies before clinical trials. [ABSTRACT FROM AUTHOR] |
|
Copyright of Molecules is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder